[18F]FDG PET/CT in the staging of inflammatory breast cancer: A systematic review

D. J.P. van Uden*, M. W. Prins, S. Siesling, J. H.W. de Wilt, C. F.J.M. Blanken-Peeters

*Corresponding author for this work

Research output: Contribution to journalReview articleAcademicpeer-review

Abstract

Up to 78 % of patients with inflammatory breast cancer (IBC) present with axillary lymph node involvement and up to 40 % with distant metastases. Previous studies indicate that 2-deoxy-2-(18F)fluoro-D-glucose ([18F]FDG) positron emission tomography/computed tomography (PET/CT) might be used for initial staging in patients with inflammatory breast cancer (IBC). In other cancer types, [18F]FDG PET/CT has been demonstrated to be a sensitive technique, providing complementary information on locoregional and distant disease to conventional imaging modalities. This systematic review showed that 18F]FDG PET/CT detects additional locoregional lymph node metastases and distant metastases in 10.3 % of patients, that were not detected with standard staging imaging. Compared with conventional imaging procedures, [18F]FDG PET/CT had better diagnostic performance for detection of locoregional and distant metastases and should standardly be used in the diagnostic work-up of IBC patients.

Original languageEnglish
Article number102943
JournalCritical Reviews in Oncology/Hematology
Volume151
DOIs
Publication statusPublished - 1 Jul 2020

Keywords

  • UT-Hybrid-D
  • Positron emission tomography
  • Staging
  • Inflammatory breast cancer

Fingerprint Dive into the research topics of '[18F]FDG PET/CT in the staging of inflammatory breast cancer: A systematic review'. Together they form a unique fingerprint.

  • Cite this